OPSENS TO PRESENT AT THE LD MICRO INVITATIONAL
22 May 2019Quebec City, Quebec, May 22, 2019 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a company focusing mainly on physiological measurements such as Fractional Flow Reserve (“FFR”) and Diastolic Pressure Ratio (“dPR”) in interventional cardiology, will present at the LD Micro 9th Invitational investor conference on Tuesday, June 4, 2019 at 8:40 am PST. Louis Laflamme, Opsens’…
OPSENS SIGNS LANDMARK SUPPLIER AGREEMENT – EXPANDS OPTICAL SENSING TECHNOLOGY IMPACT WITHIN CARDIOLOGY SEGMENT
30 April 2019Quebec City, Quebec, April 30, 2019 – Opsens inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) is pleased to announce it has entered into a supply agreement as part of its long-term collaboration with Abiomed, Inc. (“Abiomed”) for the Impella CP® heart pump. Abiomed has awarded Opsens a five-year agreement to supply a critical component for…
OPSENS – Q2 2019 REVENUES REACH $7.9 M, A 46% INCREASE
11 April 2019Quebec City, Quebec, April 11, 2019 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the second quarter of 2019. Highlights Consolidated revenues totaled $7.9 M in the second quarter of 2019 compared with $5.4 M in the corresponding period in 2018, an increase of $2.5 M or 46%; Fractional…
OPSENS APPOINTS ALAN MILINAZZO AS EXECUTIVE CHAIRMAN OF THE BOARD OF DIRECTORS
4 March 2019Quebec City, Quebec, March 4, 2019 – Opsens Inc. (“Opsens”) (TSX:OPS) (OTCQX:OPSSF) is pleased to announce the appointment of Mr. Alan Milinazzo as Executive Chairman of the Board of Directors. “We are delighted to see Alan, a renowned leader in the medical device industry, join us. Alan has had extensive success in building high-performance commercial…
OPSENS ANNOUNCES CREDIT AGREEMENT WITH CIBC INNOVATION BANKING
27 February 2019OPSENS ANNOUNCES CREDIT AGREEMENT WITH CIBC INNOVATION BANKING Quebec City, Quebec, February 27, 2019 – Opsens Inc. (“Opsens”) (TSX:OPS) (OTCQX:OPSSF) ) is pleased to announce that it has entered into an $8 M credit agreement (the “Agreement”) with CIBC Innovation Banking (CIBC). “The Agreement offered carries excellent conditions. We are proud of the confidence shown by the…
OPSENS – Q1 2019 REVENUES REACH A RECORD HIGH OF $9.1 M, A 43% INCREASE
14 January 2019Quebec City, Quebec, January 14, 2019 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the first quarter of 2019. Highlights Consolidated revenues totaled $9.1 M in the first quarter of 2019 compared with $6.4 M in the corresponding period in 2018, an increase of $2.7 M or 43% and…
OPSENS’ dPR OBTAINS CE MARKING TO SELL IN EUROPE
9 January 2019Quebec City, Quebec, January 9, 2019 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) has been granted CE marking for its diastolic pressure algorithm (“dPR”). Opsens’ dPR algorithm has been designed to assess intracoronary pressure with the heart at rest to diagnose coronary disease without the injection of heart-stimulating medication. Opsens’ diastolic pressure ratio…
OPSENS REPORTS Q4 and FY2018 RESULTS – RECORD ANNUAL REVENUE SURPASS $24 M AND RECORD QUARTERLY FFR REVENUES AT $4.1 M
28 November 2018Quebec City, Quebec, November 28, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the fourth quarter and fiscal year ended August 31, 2018. Highlights for the quarter and for the year Fractional Flow Reserve (“FFR”) revenues reach $4.1 M in the fourth quarter of 2018 compared with $2.8…
OPSENS RECEIVES HEALTH CANADA APPROVAL FOR dPR INTENDED FOR THE DIAGNOSIS OF CORONARY STENOSIS WITH THE HEART AT REST
27 November 2018Quebec City, Quebec, November 27, 2018 – Opsens Inc. (“Opsens”) (TSX:OPS) (OTCQX:OPSSF) announced today that it has obtained approval from Health Canada to market its dPR Proprietary Resting Index, which measures intracoronary pressure and establishes a diagnosis with the heart at rest to guide the treatment of patients with coronary heart disease. dPR stands for Diastolic…
OPSENS – FIRST USE OF dPR FOR THE DIAGNOSIS OF CORONARY STENOSIS WITH THE HEART AT REST
8 November 2018Quebec City, Quebec, November 8, 2018 – Opsens Inc. (“Opsens”) (TSX:OPS) (OTCQX:OPSSF) announces that its Diastolic Pressure Ratio called dPR, has been used for the first time by Dr. Hitoshi Matsuo, cardiologist and President of the Gifu Heart Center Japan. The measurement of Fractional Flow Reserve (“FFR”) as a method of assessing intracoronary pressure has gained credibility and popularity…